Crizotinib changes the metabolic pattern and inhibits ATP production in A549 non‑small cell lung cancer cells

Ye,Sa; Zhou,Hong-Bin; Chen,Ying; Li,Kai-Qiang; Jiang,Shan-Shan; Hao,Ke

doi:10.3892/ol.2020.12323

Crizotinib changes the metabolic pattern and inhibits ATP production in A549 non‑small cell lung cancer cells

Authors:
- Sa Ye
- Hong-Bin Zhou
- Ying Chen
- Kai-Qiang Li
- Shan-Shan Jiang
- Ke Hao
View Affiliations

Affiliations: Department of Nutrition, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China, Department of Respiratory Medicine, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China, Research Center of Blood Transfusion Medicine, Ministry of Education Key Laboratory of Laboratory Medicine, Department of Blood Transfusion, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China
Published online on: November 19, 2020 https://doi.org/10.3892/ol.2020.12323
Article Number: 61
Copyright: © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Crizotinib, an inhibitor of the hepatocyte growth factor receptor oncogene, has been studied extensively regarding its antitumor and clinically beneficial effects in non‑small cell lung cancer (NSCLC). However, crizotinib's effects on cancer cell energy metabolism, which is linked with tumor proliferation and migration, in NSCLC are unclear. Therefore, the present study focused on crizotinib's effect on NSCLC glucose metabolism. Crizotinib's effects on glucose metabolism, proliferation, migration and apoptosis in A549 cells were explored. Several other inhibitors, including 2‑DG, rotenone and MG132, were used to define the mechanism of action in further detail. Data showed that crizotinib treatment reduced A549 cell viability, increased glucose consumption and lactate production, while decreased mitochondrial transmembrane potential (Δψm) and ATP production. Crizotinib treatment, combined with rotenone and MG132 treatment, further inhibited ATP production and Δψm and increased reactive oxygen species content. However, crizotinib did not suppress cell proliferation, migration, ATP production, Δψm or mitochondrial‑related apoptosis signals further following 2‑DG‑mediated inhibition of glycolysis. These results indicated that crizotinib induced low mitochondrial function and compensatory high anaerobic metabolism, but failed to maintain sufficient ATP levels. The alternation of metabolic pattern and insufficient ATP supply may serve important roles in the metabolic antitumor mechanism of crizotinib in A549 cells.

View Figures

View References

1	Puxty K, Grant CH, McLoone P, Sloan B, Quasim T, Hulse K and Morrison DS: Factors associated with intensive care admission in patients with lung cancer: A population-based observational study of 26,731 patients. BMC Pulm Med. 20:362020. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Watermann I, Schmitt B, Stellmacher F, Müller J, Gaber R, Kugler C, Reinmuth N, Huber RM, Thomas M, Zabel P, et al: Improved diagnostics targeting c-MET in non-small cell lung cancer: Expression, amplification and activation? Diagn Pathol. 10:1302015. View Article : Google Scholar : PubMed/NCBI
4	Szturz P, Raymond E, Abitbol C, Albert S, de Gramont A and Faivre S: Understanding c-MET signalling in squamous cell carcinoma of the head & neck. Crit Rev Oncol Hematol. 111:39–51. 2017. View Article : Google Scholar : PubMed/NCBI
5	Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, De Guibert S, et al: Crizotinib in c-MET- or ROS1-positive NSCLC: Results of the AcSe phase II trial. Ann Oncol. 30:1985–1991. 2019. View Article : Google Scholar : PubMed/NCBI
6	Warburg O: On respiratory impairment in cancer cells. Science. 124:269–270. 1956.PubMed/NCBI
7	Zhao Y, Butler EB and Tan M: Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 4:e5322013. View Article : Google Scholar : PubMed/NCBI
8	Pan H, Wang BH, Li ZB, Gong XG, Qin Y, Jiang Y and Han WL: Mitochondrial superoxide anions induced by exogenous oxidative stress determine tumor cell fate: An individual cell-based study. J Zhejiang Univ Sci B. 20:310–321. 2019. View Article : Google Scholar : PubMed/NCBI
9	Yang D and Kim J: Mitochondrial retrograde signalling and metabolic alterations in the tumour microenvironment. Cells. 8:2752019. View Article : Google Scholar
10	LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, de Carvalho FM, Damascena A, Domingos Chinen LT, Rocha RM, et al: PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 16:992–1003, 1-15. 2014. View Article : Google Scholar : PubMed/NCBI
11	Dupuy F, Tabaries S, Andrzejewski S, Dong Z, Blagih J, Annis MG, Omeroglu A, Gao D, Leung S, Amir E, et al: PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer. Cell Metab. 22:577–589. 2015. View Article : Google Scholar : PubMed/NCBI
12	Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, et al: Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 379:2027–2039. 2018. View Article : Google Scholar : PubMed/NCBI
13	Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, Yang JJ, Yamamoto N, Ahn MJ, Takahashi T, et al: Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol. 36:1405–1411. 2018. View Article : Google Scholar : PubMed/NCBI
14	Liu Y, Liu JH, Chai K, Tashiro S, Onodera S and Ikejima T: Inhibition of c-Met promoted apoptosis, autophagy and loss of the mitochondrial transmembrane potential in oridonin-induced A549 lung cancer cells. J Pharm Pharmacol. 65:1622–1642. 2013. View Article : Google Scholar : PubMed/NCBI
15	Mingard C, Paech F, Bouitbir J and Krahenbuhl S: Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines. J Appl Toxicol. 38:418–431. 2018. View Article : Google Scholar : PubMed/NCBI
16	Hao K, Kong FP, Gao YQ, Tang JW, Chen J, Evans AM, Lightman SL, Chen XQ and Du JZ: Inactivation of corticotropin-releasing hormone-induced insulinotropic role by high-altitude hypoxia. Diabetes. 64:785–795. 2015. View Article : Google Scholar : PubMed/NCBI
17	Palorini R, Simonetto T, Cirulli C and Chiaradonna F: Mitochondrial complex I inhibitors and forced oxidative phosphorylation synergize in inducing cancer cell death. Int J Cell Biol. 2013:2438762013. View Article : Google Scholar : PubMed/NCBI
18	Zhu Z, Jiang W, McGinley JN and Thompson HJ: 2-Deoxyglucose as an energy restriction mimetic agent: Effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res. 65:7023–7030. 2005. View Article : Google Scholar : PubMed/NCBI
19	Harhouri K, Navarro C, Depetris D, Mattei MG, Nissan X, Cau P, De Sandre-Giovannoli A and Lévy N: MG132-induced progerin clearance is mediated by autophagy activation and splicing regulation. EMBO Mol Med. 9:1294–1313. 2017. View Article : Google Scholar : PubMed/NCBI
20	Liu X, Kang J, Wang H and Huang T: Mitochondrial ROS contribute to oridonin-induced HepG2 apoptosis through PARP activation. Oncol Lett. 15:2881–2888. 2018.PubMed/NCBI
21	Kim JH, Nam B, Choi YJ, Kim SY, Lee JE, Sung KJ, Kim WS, Choi CM, Chang EJ, Koh JS, et al: Enhanced glycolysis supports cell survival in EGFR-mutant lung adenocarcinoma by inhibiting autophagy-mediated EGFR degradation. Cancer Res. 78:4482–4496. 2018. View Article : Google Scholar : PubMed/NCBI
22	Anemone A, Consolino L, Arena F, Capozza M and Longo DL: Imaging tumor acidosis: A survey of the available techniques for mapping in vivo tumor pH. Cancer Metastasis Rev. 38:25–49. 2019. View Article : Google Scholar : PubMed/NCBI
23	Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F and Lisanti MP: Cancer metabolism: A therapeutic perspective. Nat Rev Clin Oncol. 14:1132017. View Article : Google Scholar : PubMed/NCBI
24	Avagliano A, Ruocco MR, Aliotta F, Belviso I, Accurso A, Masone S, Montagnani S and Arcucci A: Mitochondrial flexibility of breast cancers: A growth advantage and a therapeutic opportunity. Cells. 8:4012019. View Article : Google Scholar
25	Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR and Chandel NS: Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA. 107:8788–8793. 2010. View Article : Google Scholar : PubMed/NCBI
26	Vyas S, Zaganjor E and Haigis MC: Mitochondria and cancer. Cell. 166:555–566. 2016. View Article : Google Scholar : PubMed/NCBI
27	Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, Armistead S, Lemire K, Orrell J, Teich J, et al: Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol. 292:C125–C136. 2007. View Article : Google Scholar : PubMed/NCBI
28	Kumar D, New J, Vishwakarma V, Joshi R, Enders J, Lin F, Dasari S, Gutierrez WR, Leef G, Ponnurangam S, et al: Cancer-associated fibroblasts drive glycolysis in a targetable signaling loop implicated in head and neck squamous cell carcinoma progression. Cancer Res. 78:3769–3782. 2018. View Article : Google Scholar : PubMed/NCBI
29	Hensley CT, Faubert B, Yuan Q, Lev-Cohain N, Jin E, Kim J, Jiang L, Ko B, Skelton R, Loudat L, et al: Metabolic heterogeneity in human lung tumors. Cell. 164:681–694. 2016. View Article : Google Scholar : PubMed/NCBI
30	Faubert B, Li KY, Cai L, Hensley CT, Kim J, Zacharias LG, Yang C, Do QN, Doucette S, Burguete D, et al: Lactate metabolism in human lung tumors. Cell. 171:358–371.e9. 2017. View Article : Google Scholar : PubMed/NCBI
31	Cruz-Bermúdez A, Vicente-Blanco RJ, Laza-Briviesca R, García-Grande A, Laine-Menéndez S, Gutiérrez L, Calvo V, Romero A, Martín-Acosta P, García JM and Provencio M: PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy. Sci Rep. 7:166612017. View Article : Google Scholar : PubMed/NCBI
32	O'Neill S, Porter RK, McNamee N, Martinez VG and O'Driscoll L: 2-Deoxy-D-Glucose inhibits aggressive triple-negative breast cancer cells by targeting glycolysis and the cancer stem cell phenotype. Sci Rep. 9:37882019. View Article : Google Scholar : PubMed/NCBI
33	Maximchik P, Abdrakhmanov A, Inozemtseva E, Tyurin-Kuzmin PA, Zhivotovsky B and Gogvadze V: 2-Deoxy-D-glucose has distinct and cell line-specific effects on the survival of different cancer cells upon antitumor drug treatment. FEBS J. 285:4590–4601. 2018. View Article : Google Scholar : PubMed/NCBI
34	Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, et al: A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 71:523–530. 2013. View Article : Google Scholar : PubMed/NCBI
35	Brohée L, Peulen O, Nusgens B, Castronovo V, Thiry M, Colige AC and Deroanne CF: Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression. Sci Rep. 8:70502018. View Article : Google Scholar : PubMed/NCBI
36	Guerra-Castellano A, Díaz-Quintana A, Pérez-Mejías G, Elena-Real CA, González-Arzola K, García-Mauriño SM, De la Rosa MA and Díaz-Moreno I: Oxidative stress is tightly regulated by cytochrome c phosphorylation and respirasome factors in mitochondria. Proc Natl Acad Sci USA. 115:7955–7960. 2018. View Article : Google Scholar : PubMed/NCBI
37	Peña-Blanco A and García-Sáez AJ: Bax, Bak and beyond-mitochondrial performance in apoptosis. FEBS J. 285:416–431. 2018. View Article : Google Scholar : PubMed/NCBI
38	Lu H, Wu S, Chen H, Huang Y, Qiu G, Liu L and Li Y: Crizotinib induces apoptosis of lung cancer cells through JAK-STAT pathway. Oncol Lett. 16:5992–5996. 2018.PubMed/NCBI
39	You L, Shou J, Deng D, Jiang L, Jing Z, Yao J, Li H, Xie J, Wang Z, Pan Q, et al: Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines. Oncotarget. 6:40268–40282. 2015. View Article : Google Scholar : PubMed/NCBI
40	Kimmelman AC and White E: Autophagy and tumor metabolism. Cell Metab. 25:1037–1043. 2017. View Article : Google Scholar : PubMed/NCBI